专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017046794A1 NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION 审中-公开
标题翻译：新型哌嗪和哌啶衍生物，它们的合成及其在抑制VDAC低分化，抗病毒和麻醉药物功能中的用途
公开(公告)号：WO2017046794A1
公开(公告)日：2017-03-23
申请号：PCT/IL2016/051020
申请日：2016-09-13
申请人： THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.
发明人： SHOSHAN-BARMATZ, Varda , LEV GRUZMAN, Arie
IPC分类号： C07D471/10 , A61K31/445 , A61K31/495 , C07D241/54 , A61P43/00 , C07D211/58 , C07D295/06 , C07D241/04 , C07D403/04 , A61P9/00 , A61P25/00 , A61P25/16 , A61P25/08
CPC分类号： C07D295/15 , A61K31/435 , A61K31/445 , A61K31/454 , A61K31/4965 , A61P9/00 , A61P9/06 , A61P25/16 , A61P25/28 , C07D207/273 , C07D207/36 , C07D207/416 , C07D211/66 , C07D401/04 , C07D471/10
摘要： Provided herein piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction. Also provided methods of treatment of diseases associated with said processes, e.g. Alzheimer's disease.
摘要翻译：提供哌嗪和哌啶衍生物，其合成及其在抑制VDAC低聚，凋亡和线粒体功能障碍中的用途。还提供了治疗与所述方法相关的疾病的方法，例如。阿尔茨海默氏病。

2. 发明申请

WO0006146A9 SUBSTITUTED ANILIDE COMPOUNDS AND METHODS 审中-公开
标题翻译：取代的苯胺化合物和方法
公开(公告)号：WO0006146A9
公开(公告)日：2000-08-03
申请号：PCT/US9917121
申请日：1999-07-28
申请人： SMITHKLINE BEECHAM CORP , KU THOMAS W , BONDINELL WILLIAM E , NEEB MICHAEL J
发明人： KU THOMAS W , BONDINELL WILLIAM E , NEEB MICHAEL J
IPC分类号： C07D215/38 , A61K31/00 , A61K31/167 , A61K31/18 , A61K31/426 , A61K31/438 , A61K31/4427 , A61K31/445 , A61K31/4453 , A61K31/47 , A61K31/498 , A61K31/538 , A61P1/00 , A61P11/06 , A61P17/06 , A61P19/02 , A61P29/00 , A61P37/00 , A61P37/06 , A61P37/08 , C07C233/75 , C07C235/42 , C07C235/56 , C07C235/84 , C07C237/40 , C07C251/48 , C07C311/39 , C07C317/44 , C07D211/14 , C07D215/06 , C07D241/54 , C07D265/36 , C07D277/20 , C07D277/46 , C07D277/56 , C07D295/092 , C07D401/12 , C07D491/10 , C07D491/107 , A61K31/165 , C07D235/56
CPC分类号： C07D295/088 , A61K31/00 , A61K31/167 , A61K31/18 , A61K31/426 , A61K31/438 , A61K31/445 , A61K31/47 , A61K31/498 , A61K31/538 , A61K31/5383 , C07C233/75 , C07C235/42 , C07C235/56 , C07C235/84 , C07C237/40 , C07C251/48 , C07C311/39 , C07C317/44 , C07D215/06 , C07D241/54 , C07D265/36 , C07D277/56 , C07D491/10
摘要： This invention relates to substituted anilide compounds which are modulators, agonists or antagonists, of the CCR5 receptor. In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5.
摘要翻译：本发明涉及作为CCR5受体的调节剂，激动剂或拮抗剂的取代的酰苯胺化合物。此外，本发明涉及治疗和预防由CCR5介导的疾病状态。

3. 发明申请

WO0076984A3 NOVEL COMPOUNDS, THEIR USE AND PREPARATION 审中-公开
标题翻译：新化合物，其使用和制备
公开(公告)号：WO0076984A3
公开(公告)日：2001-02-08
申请号：PCT/SE0001017
申请日：2000-05-19
申请人： PHARMACIA & UPJOHN AB , NILSSON BJOERN , TEJBRANT JAN , PELCMAN BENJAMIN , RINGBERG ERIK , THOR MARKUS , NILSSON JONAS , JOENSSON MATTIAS
发明人： NILSSON BJOERN , TEJBRANT JAN , PELCMAN BENJAMIN , RINGBERG ERIK , THOR MARKUS , NILSSON JONAS , JOENSSON MATTIAS
IPC分类号： A61K31/497 , A61K31/498 , A61K31/517 , A61K31/5377 , A61K31/551 , A61P3/04 , A61P13/00 , A61P15/00 , A61P25/00 , A61P25/04 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D241/18 , C07D241/20 , C07D241/54 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D491/04
CPC分类号： C07D401/12 , C07D241/18 , C07D241/20 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D491/04
摘要： The invention relates to compounds of general formula (I) wherein Ar is optionally substituted aryl or heteroaryl; A is (i) -O-, -S-, -SO2-, -NH-, (ii) a C1-4-alkyl- or C1-6-acyl-substituted nitrogen atom or (iii) a C1-8-alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members; B is -C(R4)(R5)-, -OC(R4)(R5)-, -N(R6)C(R4)(R5)-, -N(R6)-O-, -S- or -SO2-; R is optionally substituted C3-8-cycloalkyl, aryl or heteroaryl; R1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group -[C(R4)(R5)]xN(R2a)(R3a)]; R2a, R3a, R4, R5, R6 and x are as defined in the claims, and n is 0 or 1; and pharmaceutically acceptable salts, hydrates and prodrug forms thereof. The compounds may be prepared by per se conventional methods and can be used for treating a human or animal subject suffering from a serotonin-related disorder, such as eating disorders, especially obesity, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctions, and urinary disorders. The invention also relates to such use as well as to pharmaceutical compositions comprising a compound of formula (I).
摘要翻译：本发明涉及通式（I）的化合物，其中Ar为任选取代的芳基或杂芳基; A是（ⅰ）-O - ， - S - ， - SO 2 - ， - NH - ，（ⅱ）C 1-4 - 烷基 - 或C 1-6 - 酰基取代的氮原子或（ⅲ）亚烷基链或具有2至8个链原子的杂亚烷基链，其任选地包含至少一个不饱和键，并且其可以被取代和/或含有桥以形成具有3-8个环成员的饱和或部分或完全不饱和的环; B是-C（R4）（R5） - ，-OC（R4）（R5） - ， - N（R6）C（R4）（R5） - ，-N（R6）-O - ， - S-或 - SO2-; R是任选取代的C 3-8 - 环烷基，芳基或杂芳基; R1是（i）饱和或不饱和的氮杂环或氨基氮杂环，或具有4-7个环成员的饱和二氮环或氨基二氮环，或具有7至10个环成员的饱和氨基氮杂双环，氮杂双环或二氮杂双环，其任选地在一个或多个位置被取代，或基团 - [C（R 4）（R 5）] x N（R 2a）（R 3a）]; R2a，R3a，R4，R5，R6和x如权利要求中所定义，n为0或1; 及其药学上可接受的盐，水合物和前药形式。化合物可以通过本身的常规方法制备，并且可以用于治疗患有5-羟色胺相关病症的人或动物受试者，例如进食障碍，特别是肥胖症，记忆障碍，精神分裂症，情绪障碍，焦虑症，疼痛，性功能障碍和尿失调。本发明还涉及这样的用途以及包含式（I）化合物的药物组合物。

4. 发明申请

WO0031051B1 QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-RECEPTOR AND/OR LCK TYROSINE KINASE INHIBITORS 审中-公开
标题翻译：喹啉和喹啉化合物作为PDGF受体和/或LCK酪氨酸激酶抑制剂
公开(公告)号：WO0031051B1
公开(公告)日：2000-08-27
申请号：PCT/US9927825
申请日：1999-11-23
申请人： AVENTIS PHARM PROD INC , MYERS MICHAEL R , HE WEI , SPADA ALFRED P , MAGUIRE MARTIN P
发明人： MYERS MICHAEL R , HE WEI , SPADA ALFRED P , MAGUIRE MARTIN P
IPC分类号： A61F2/84 , A61K31/47 , A61K31/495 , A61K31/498 , A61K31/5377 , A61M25/00 , A61P9/00 , A61P9/10 , A61P17/06 , A61P19/08 , A61P29/00 , A61P35/00 , A61P35/02 , A61P43/00 , C07D215/20 , C07D215/38 , C07D241/42 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/10 , C07D405/12 , C07D453/06 , C07D471/08 , A61K31/50
CPC分类号： C07D215/38 , C07D215/20 , C07D241/42 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12 , C07D453/06
摘要： This invention is directed to quinoline/quinoxaline compounds of formula (I), which inhibit platelet-derived growth factor or p56 tyrosine kinase activity, to pharmaceutical compositions comprising theses compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
摘要翻译：本发明涉及抑制血小板衍生生长因子或p56酪氨酸激酶活性的式（I）的喹啉/喹喔啉化合物，包括这些化合物的药物组合物，以及这些化合物用于治疗患者的用途来自或受到涉及细胞分化，增殖，细胞外基质产生或介体释放和/或T细胞活化和增殖的病症/病症的影响。

5. 发明申请

WO0076984A8 NOVEL COMPOUNDS, THEIR USE AND PREPARATION 审中-公开
标题翻译：新化合物，它们的用途和制备
公开(公告)号：WO0076984A8
公开(公告)日：2001-07-19
申请号：PCT/SE0001017
申请日：2000-05-19
申请人： PHARMACIA AB , NILSSON BJOERN , TEJBRANT JAN , PELCMAN BENJAMIN , RINGBERG ERIK , THOR MARKUS , NILSSON JONAS , JOENSSON MATTIAS
发明人： NILSSON BJOERN , TEJBRANT JAN , PELCMAN BENJAMIN , RINGBERG ERIK , THOR MARKUS , NILSSON JONAS , JOENSSON MATTIAS
IPC分类号： A61K31/497 , A61K31/498 , A61K31/517 , A61K31/5377 , A61K31/551 , A61P3/04 , A61P13/00 , A61P15/00 , A61P25/00 , A61P25/04 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D241/18 , C07D241/20 , C07D241/54 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D491/04
CPC分类号： C07D401/12 , C07D241/18 , C07D241/20 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D491/04
摘要： The invention relates to compounds of general formula (I) wherein Ar is optionally substituted aryl or heteroaryl; A is (i) -O-, -S-, -SO2-, -NH-, (ii) a C1-4-alkyl- or C1-6-acyl-substituted nitrogen atom or (iii) a C1-8-alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members; B is -C(R4)(R5)-, -OC(R4)(R5)-, -N(R6)C(R4)(R5)-, -N(R6)-O-, -S- or -SO2-; R is optionally substituted C3-8-cycloalkyl, aryl or heteroaryl; R1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group -[C(R4)(R5)]xN(R2a)(R3a)]; R2a, R3a, R4, R5, R6 and x are as defined in the claims, and n is 0 or 1; and pharmaceutically acceptable salts, hydrates and prodrug forms thereof. The compounds may be prepared by per se conventional methods and can be used for treating a human or animal subject suffering from a serotonin-related disorder, such as eating disorders, especially obesity, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctions, and urinary disorders. The invention also relates to such use as well as to pharmaceutical compositions comprising a compound of formula (I).
摘要翻译：本发明涉及通式（I）的化合物，其中Ar是任选取代的芳基或杂芳基; A为（i）-O - ， - S - ， - SO2 - ， - NH-，（ii）C1-4-烷基 - 或C1-6-酰基取代的氮原子或（iii）C1-8- 亚烷基链或具有2-8个链原子的杂亚烷基链，其任选地含有至少一个不饱和键，并且其可以被取代和/或含有桥以形成具有3-8个环成员的饱和或部分或完全不饱和的环; （R 4）（R 5） - ， - O（R 4）（R 5） - ， - N（R 6）C SO2-; R是任选取代的C 3-8 - 环烷基，芳基或杂芳基; R1为（i）饱和或不饱和的氮杂环或氨基氮杂环或饱和的二氮杂环或氨基二氮杂环，其具有4至7个环成员，或具有7至10个环成员的饱和氨基氮杂二环，氮杂二环或二氮杂双环，在一个或多个位置被取代，或基团 - [C（R4）（R5）] xN（R2a）（R3a）]; R2a，R3a，R4，R5，R6和x如权利要求中所定义，且n为0或1; 及其药学上可接受的盐，水合物和前药形式。这些化合物可以通过本身常规方法制备，并且可以用于治疗患有血清素相关病症的人或动物对象，例如进食障碍，尤其是肥胖症，记忆障碍，精神分裂症，心境障碍，焦虑症，疼痛，性功能障碍和泌尿系统疾病。本发明还涉及这种用途以及包含式（I）化合物的药物组合物。

6. 发明申请

WO00076984A2 NOVEL COMPOUNDS, THEIR USE AND PREPARATION 审中-公开
标题翻译：新化合物，其使用和制备
公开(公告)号：WO00076984A2
公开(公告)日：2000-12-21
申请号：PCT/SE2000/001017
申请日：2000-05-19
IPC分类号： A61K31/497 , A61K31/498 , A61K31/517 , A61K31/5377 , A61K31/551 , A61P3/04 , A61P13/00 , A61P15/00 , A61P25/00 , A61P25/04 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D241/18 , C07D241/20 , C07D241/54 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D491/04
CPC分类号： C07D401/12 , C07D241/18 , C07D241/20 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D491/04
摘要： The invention relates to compounds of general formula (I) wherein Ar is optionally substituted aryl or heteroaryl; A is (i) -O-, -S-, -SO2-, -NH-, (ii) a C1-4-alkyl- or C1-6-acyl-substituted nitrogen atom or (iii) a C1-8-alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members; B is -C(R4)(R5)-, -OC(R4)(R5)-, -N(R6)C(R4)(R5)-, -N(R6)-O-, -S- or -SO2-; R is optionally substituted C3-8-cycloalkyl, aryl or heteroaryl; R1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group -[C(R4)(R5)]xN(R2a)(R3a)]; R2a, R3a, R4, R5, R6 and x are as defined in the claims, and n is 0 or 1; and pharmaceutically acceptable salts, hydrates and prodrug forms thereof. The compounds may be prepared by per se conventional methods and can be used for treating a human or animal subject suffering from a serotonin-related disorder, such as eating disorders, especially obesity, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctions, and urinary disorders. The invention also relates to such use as well as to pharmaceutical compositions comprising a compound of formula (I).
摘要翻译：本发明涉及通式（I）的化合物，其中Ar为任选取代的芳基或杂芳基; A是（ⅰ）-O - ， - S - ， - SO 2 - ， - NH - ，（ⅱ）C 1-4 - 烷基 - 或C 1-6 - 酰基取代的氮原子或（ⅲ）亚烷基链或具有2至8个链原子的杂亚烷基链，其任选地包含至少一个不饱和键，并且其可以被取代和/或含有桥以形成具有3-8个环成员的饱和或部分或完全不饱和的环; B是-C（R4）（R5） - ，-OC（R4）（R5） - ， - N（R6）C（R4）（R5） - ，-N（R6）-O - ， - S-或 - SO2-; R是任选取代的C 3-8 - 环烷基，芳基或杂芳基; R1是（i）饱和或不饱和的氮杂环或氨基氮杂环，或具有4-7个环成员的饱和二氮环或氨基二氮环，或具有7至10个环成员的饱和氨基氮杂双环，氮杂双环或二氮杂双环，其任选地在一个或多个位置被取代，或基团 - [C（R 4）（R 5）] x N（R 2a）（R 3a）]; R2a，R3a，R4，R5，R6和x如权利要求中所定义，n为0或1; 及其药学上可接受的盐，水合物和前药形式。化合物可以通过本身的常规方法制备，并且可以用于治疗患有5-羟色胺相关病症的人或动物受试者，例如进食障碍，特别是肥胖症，记忆障碍，精神分裂症，情绪障碍，焦虑症，疼痛，性功能障碍和尿失调。本发明还涉及这样的用途以及包含式（I）化合物的药物组合物。

7. 发明申请

WO00031050A1 QUINOLINE AND QUINOXALINE COMPOUNDS 审中-公开
标题翻译：喹啉和喹啉化合物
公开(公告)号：WO00031050A1
公开(公告)日：2000-06-02
申请号：PCT/US1999/027761
申请日：1999-11-23
IPC分类号： A61K31/47 , A61K31/498 , A61P9/00 , A61P29/00 , A61P35/00 , A61P43/00 , C07D215/20 , C07D215/38 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12 , A61K31/495
CPC分类号： C07D215/38 , C07D215/20 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12
摘要： This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use fo these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
摘要翻译：本发明涉及抑制血小板衍生生长因子酪氨酸激酶和/或Lck酪氨酸激酶的喹啉/喹喔啉化合物，包含这些化合物的药物组合物，以及这些化合物用于治疗患有或患有疾病/ 涉及细胞分化，增殖，细胞外基质产生或介体释放和/或T细胞活化和增殖的条件。

8. 发明申请

WO98054158A1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56 TYROSINE KINASES 审中-公开
标题翻译：喹啉和喹啉化合物，其抑制片剂衍生的生长因子和/或p56 酪氨酸激酶
公开(公告)号：WO98054158A1
公开(公告)日：1998-12-03
申请号：PCT/US1998/011036
申请日：1998-05-28
IPC分类号： A61K20060101 , A61K31/47 , A61K31/495 , A61K31/498 , A61K31/5377 , A61P9/00 , A61P9/10 , A61P17/06 , A61P19/08 , A61P29/00 , A61P35/00 , A61P35/02 , A61P43/00 , C07D20060101 , C07D215/20 , C07D215/38 , C07D241/42 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/10 , C07D405/12 , C07D453/06
CPC分类号： C07D215/38 , C07D215/20 , C07D241/42 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12 , C07D453/06
摘要： This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56 tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
摘要翻译：本发明涉及抑制血小板衍生生长因子或p56酪氨酸激酶活性的喹啉/喹喔啉化合物，包含这些化合物的药物组合物，以及这些化合物用于治疗患有或患有疾病/ 涉及细胞分化，增殖，细胞外基质产生或介体释放和/或T细胞活化和增殖的条件。

9. 发明申请

WO1997032859A1 DIHYDROPHENAZINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND DRUGS FOR TUBERCLE BACILLI AND ATYPICAL ACID-FAST BACTERIA 审中-公开
标题翻译：二氢衍生物衍生物，其制备方法，以及用于管状巴氏杆菌和原位酸性快速细菌的药物
公开(公告)号：WO1997032859A1
公开(公告)日：1997-09-12
申请号：PCT/JP1996003410
申请日：1996-11-21
申请人： OTSUKA PHARMACEUTICAL CO., LTD. , KIKUCHI, Mikio , ISHIKAWA, Hiroshi , HORIMOTO, Hideaki , TSUBOUCHI, Hidetsugu , SHITSUTA, Takuya , SASAKI, Hirofumi , ITOTANI, Motohiro
发明人： OTSUKA PHARMACEUTICAL CO., LTD.
IPC分类号： C07D241/54
CPC分类号： C07D241/46
摘要： Dihydrophenazine derivatives having antibiotic effects on tubercle bacilli and atypical acid-fast bacteria and represented by general formula (1) and pharmacologically acceptable salts thereof, wherein R , R , R , R an n are each as defined in the specification.
摘要翻译：由通式（1）及其药理学上可接受的盐代表的对结核杆菌和非典型耐酸菌具有抗菌作用的二氢吩嗪衍生物，其中R 1，R 2，R 3，R 4和n 各自如说明书中所定义。

10. 发明申请

WO2022076629A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR 审中-公开
公开(公告)号：WO2022076629A1
公开(公告)日：2022-04-14
申请号：PCT/US2021/053865
申请日：2021-10-06
申请人： VERTEX PHARMACEUTICALS INCORPORATED
发明人： MCCARTNEY, Jason , ABRAHAM, Sunny , ANDERSON, Corey Don , ARUMUGAM, Vijayalaksmi , CHAU, Jaclyn , CLEVELAND, Thomas , DWIGHT, Timothy A. , FRIEMAN, Bryan A. , GROOTENHUIS, Peter (Deceased) , HADIDA RUAH, Sara Sabina , ISHIHARA, Yoshihiro , MILLER, Mark Thomas , SILINA, Alina , ZHOU, Jinglan
IPC分类号： C07D403/12 , C07D215/40 , C07D235/30 , C07D239/70 , C07D241/54 , C07D277/82 , C07D279/08 , C07D471/04 , C07D491/04 , C07D513/04 , A61P43/00 , A61K31/517 , A61K31/541 , A61K31/4375 , A61K31/4365
摘要： This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions, containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, combination therapies, and processes and intermediates for making such modulators.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式